Core Insights - Eupraxia Pharmaceuticals reported a net loss of $8.7 million for Q2 2025, an increase from a net loss of $6.1 million in Q2 2024, primarily due to rising research and development costs [4] - The company had cash reserves of $19.8 million as of June 30, 2025, down from $33.1 million at the end of Q4 2024, with expectations to fund operations into Q3 2026 [5][6] - The Phase 2b portion of the RESOLVE trial for EP-104GI has commenced, with topline data expected in the second half of 2026 [2][8] Financial Performance - The increase in net loss for Q2 2025 was attributed to higher research and development, general and administrative costs, and other expenses [4] - Cash reserves decreased significantly, indicating a need for careful financial management as the company funds ongoing clinical trials [5] - The company anticipates that existing cash and potential proceeds from in-the-money warrants will sustain operations until at least Q3 2026 [6] Clinical Development - The Phase 2b trial for EP-104GI aims to enroll at least 60 patients across 25 sites globally, focusing on treatment outcomes for eosinophilic esophagitis (EoE) [9] - Recent data from the Phase 1b/2a RESOLVE trial showed sustained positive treatment outcomes in patients after nine months, with no serious adverse events reported [8][9] - The company is optimistic about the potential of EP-104GI to transform the treatment landscape for EoE, with further data updates expected in October 2025 [3][8] Upcoming Events - Eupraxia's management is scheduled to present at several investor conferences, including the Canaccord Growth Conference and the Citi Biopharma Back to School Conference, providing opportunities for investor engagement [12][13]
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update